Geode Capital Management
EDIT icon

Geode Capital Management’s Editas Medicine EDIT Stock Holding History

Geode Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.33M Buy
2,569,072
+257,283
+11% +$752K ﹤0.01% 2645
2026
Q1 		$5.71M Buy
2,311,789
+27,049
+1% +$57.2K ﹤0.01% 2672
2025
Q4 		$4.68M Buy
2,284,740
+244,574
+12% +$706K ﹤0.01% 2819
2025
Q3 		$7.08M Buy
2,040,166
+75,868
+4% +$212K ﹤0.01% 2607
2025
Q2 		$4.32M Buy
1,964,298
+20,521
+1% +$33.6K ﹤0.01% 2803
2025
Q1 		$2.26M Buy
1,943,777
+135,214
+7% +$199K ﹤0.01% 2995
2024
Q4 		$2.3M Sell
1,808,563
-79,133
-4% -$202K ﹤0.01% 3080
2024
Q3 		$6.44M Sell
1,887,696
-78,126
-4% -$340K ﹤0.01% 2629
2024
Q2 		$9.18M Buy
1,965,822
+21,059
+1% +$119K ﹤0.01% 2375
2024
Q1 		$14.4M Buy
1,944,763
+43,028
+2% +$358K ﹤0.01% 2107
2023
Q4 		$19.3M Buy
1,901,735
+93,756
+5% +$823K ﹤0.01% 1947
2023
Q3 		$14.1M Buy
1,807,979
+315,156
+21% +$2.7M ﹤0.01% 2046
2023
Q2 		$12.3M Buy
1,492,823
+41,569
+3% +$362K ﹤0.01% 2164
2023
Q1 		$10.5M Buy
1,451,254
+71,571
+5% +$636K ﹤0.01% 2224
2022
Q4 		$12.2M Buy
1,379,683
+123,163
+10% +$1.35M ﹤0.01% 2118
2022
Q3 		$15.4M Buy
1,256,520
+29,890
+2% +$466K ﹤0.01% 1929
2022
Q2 		$14.5M Buy
1,226,630
+90,284
+8% +$1.21M ﹤0.01% 1992
2022
Q1 		$21.6M Sell
1,136,346
-84,025
-7% -$1.56M ﹤0.01% 1848
2021
Q4 		$32.4M Buy
1,220,371
+25,283
+2% +$870K ﹤0.01% 1630
2021
Q3 		$49.1M Sell
1,195,088
-10,183
-0.8% -$558K 0.01% 1294
2021
Q2 		$68.3M Buy
1,205,271
+51,906
+5% +$1.92M 0.01% 1045
2021
Q1 		$48.4M Buy
1,153,365
+188,192
+19% +$10.7M 0.01% 1260
2020
Q4 		$67.7M Buy
965,173
+33,981
+4% +$1.4M 0.01% 903
2020
Q3 		$26.1M Buy
931,192
+41,513
+5% +$1.35M 0.01% 1327
2020
Q2 		$26.3M Buy
889,679
+105,111
+13% +$2.75M 0.01% 1296
2020
Q1 		$15.6M Buy
784,568
+74,818
+11% +$1.89M ﹤0.01% 1468
2019
Q4 		$21M Buy
709,750
+67,536
+11% +$1.69M ﹤0.01% 1535
2019
Q3 		$14.6M Buy
642,214
+36,812
+6% +$912K ﹤0.01% 1676
2019
Q2 		$15M Buy
605,402
+61,804
+11% +$1.48M ﹤0.01% 1680
2019
Q1 		$13.3M Buy
543,598
+38,483
+8% +$871K ﹤0.01% 1700
2018
Q4 		$11.5M Buy
505,115
+51,295
+11% +$1.4M ﹤0.01% 1692
2018
Q3 		$14.4M Buy
453,820
+7,105
+2% +$230K ﹤0.01% 1650
2018
Q2 		$16M Buy
446,715
+89,734
+25% +$3.18M ﹤0.01% 1521
2018
Q1 		$11.8M Buy
356,981
+67,126
+23% +$2.39M ﹤0.01% 1648
2017
Q4 		$8.91M Buy
289,855
+51,059
+21% +$1.29M ﹤0.01% 1826
2017
Q3 		$5.73M Sell
238,796
-46,283
-16% -$881K ﹤0.01% 2116
2017
Q2 		$4.78M Buy
285,079
+165,703
+139% +$2.99M ﹤0.01% 2171
2017
Q1 		$2.66M Buy
119,376
+5,397
+5% +$112K ﹤0.01% 2492
2016
Q4 		$1.85M Buy
113,979
+11,335
+11% +$172K ﹤0.01% 2674
2016
Q3 		$1.38M Buy
102,644
+45,875
+81% +$940K ﹤0.01% 2767
2016
Q2 		$1.39M Sell
56,769
-40
-0.1% -$1.35K ﹤0.01% 2721
2016
Q1 		$1.96K Buy
+56,809
New +$1.49M ﹤0.01% 2478

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management's EDIT Position: Q2 2026 in Review

Geode Capital Management increased its Editas Medicine (EDIT) stake by 11% in Q2 2026, buying an estimated $752K and bringing the position to 2,569,072 shares worth $8.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Geode Capital Management first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $68.3M in Q2 2021. 213 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Geode Capital Management held 2,569,072 shares of Editas Medicine worth $8.33M as of Q2 2026.
  • Geode Capital Management bought 257,283 Editas Medicine shares in Q2 2026, an estimated $752K.
  • Editas Medicine made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2645 holding.
  • Geode Capital Management first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Geode Capital Management's Editas Medicine position peaked at $68.3M in Q2 2021.
  • 213 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.